

COMMUNITY PROGRAMMES

CAPRISA recognizes that community engagement and partnerships with informed communities is critical to the successful and ethical conduct of research. Community Advisory Boards are in place to support research studies and work closely with the CAPRISA Community Core Team.



Patrick Mdletshe

CAPRISA Head of Community Programmes



Generating Knowledge - Impacting Health

The Centre for the AIDS Programme of Research in South Africa (CAPRISA) is recognized as a world-renowned HIV and TB research organization. CAPRISA undertakes high-impact globally relevant and locally responsive research on HIV, TB and SARS-CoV-2 epidemiology, pathogenesis, prevention and treatment. CAPRISA is an official research centre of the University of KwaZulu-Natal (UKZN) and Columbia University in New York. It is a designated UNAIDS Collaborating Centre for HIV Research and Policy.



Bongive Ntuli

Chair: CAPRISA Board of Control, Chief Executive Officer of the Foschini Group



Professor Françoise Barré-Sinoussi, Nobel Laureate

Chair: CAPRISA Scientific Advisory Board, Emeritus Professor, Institut Pasteur and Emeritus Director of Research, Inserm

CONTACT DETAILS

Centre for the AIDS Programme of Research in South Africa (CAPRISA)
Doris Duke Medical Research Institute (DDMRI)
University of KwaZulu-Natal, Private Bag X7, Congella 4013
T: +27 - 31 655 0500 • F: + 27 - 31 260 4549
Website: www.caprisa.org • Email: caprisa@caprisa.org



Globally Relevant and Locally Responsive HIV Prevention and Treatment Research



“CAPRISA combines scientific rigour with creativity to find real solutions to the HIV epidemic and thereby impact on global health and well-being”

*Professor Salim Abdool Karim
Director, CAPRISA*

RESEARCH PROGRAMMES

EPIDEMIOLOGY AND PREVENTION

Epidemiological studies monitor the evolving HIV epidemic; identify socio-behavioural and biological factors that contribute to young women's increased risk of HIV infection; and evaluate new HIV prevention strategies.

VACCINE AND PATHOGENESIS

The vaccine and pathogenesis programme aims to advance both passive immunization and vaccine strategies to reduce HIV incidence among young women in South Africa

HIV AND TB TREATMENT

The TB-HIV Treatment Research Programme undertakes clinical studies aimed at reducing death among TB-HIV co-infected patients.



MUCOSAL IMMUNOLOGY

The Mucosal Immunology Laboratory focuses on investigating cutting edge concepts in mucosal immunology that are relevant to preventing HIV infection in women.

CAPRISA hosts a DSI-NRF Centre of Excellence (CoE) in HIV Prevention and a MRC HIV-TB Pathogenesis and Treatment Research Unit

RESEARCH CLINICS



The **Umlazi Clinical Research Site (CRS)** also known as the Philasande is located adjacent to the Prince Mshyeni Hospital (PMMH). The Site conducts studies to prevent mother-to-child transmission (PMTCT) of HIV.



The **Vulindlela CAPRISA Research Clinic** adjoins the Mafakatini Primary Health Care Clinic in the rural Vulindlela district in KwaZulu-Natal. This research facility works closely with the local community to study new approaches to HIV prevention and treatment.



The **eThekweni CAPRISA Research Clinic** adjoins the Prince Cyril Zulu Communicable Disease Centre, which is the largest government outpatient TB and sexually transmitted diseases treatment facility in Durban.



The **Springfield CAPRISA Research Clinic** at the King Dinuzulu Hospital, which is the largest TB referral hospital in the province of KwaZulu-Natal. CAPRISA's research here focuses on clinical studies on MDR-TB and XDR-TB.

